Tags

Type your tag names separated by a space and hit enter

Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection.
Public Health. 2021 Apr; 193:113-115.PH

Abstract

OBJECTIVE

The aim of the study was to evaluate factors predicting severe symptomatic laboratory-confirmed (via Reverse transcription polymerase chain reaction, RT-PCR polymerase chain reaction) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection.

STUDY DESIGN

This is a nationwide retrospective cohort study that was conducted in Mexico.

METHODS

Data from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RRs) and 95% confidence intervals (CIs) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-CoV-2 infection.

RESULTS

The risk of severe disease was 14.7%, and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, P < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-CoV-2 reinfection were increasing age (RRper year = 1.007, 95% CI = 1.003-1.010), comorbidities (namely, obesity [RR = 1.12, 95% CI = 1.01-1.24], asthma [RR = 1.26, 95% CI = 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI = 1.07-1.38]), and previous severe laboratory-confirmed coronavirus disease 2019 (RR = 1.20, 95% CI = 1.03-1.39).

CONCLUSIONS

To the best of our knowledge, this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-CoV-2 reinfection, and factors associated with illness severity were characterized. Our results may contribute to the current knowledge of SARS-CoV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.

Authors+Show Affiliations

Departamento de Epidemiología, Unidad de Medicina Familiar No. 19, Instituto Mexicano del Seguro Social, Av. Javier Mina 301, Col. Centro, C.P. 28000, Colima, Colima, Mexico; Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, Mexico. Electronic address: efren.murilloza@imss.gob.mx.Facultad de Ingeniería Civil, Universidad de Colima, Km. 9 Carretera Colima-Coquimatlán, Coquimatlán, C.P. 28400, Colima, Mexico. Electronic address: oliver@ucol.mx.Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, Mexico; Instituto Estatal de Cancerología de los Servicios de Salud del Estado de Colima, Av. Liceo de Varones 401, Col. La Esperanza, C.P 28085, Colima, Colima, Mexico. Electronic address: ivan_delgado_enciso@ucol.mx.Facultad de Ciencias, Universidad de Colima, Bernal Díaz del Castillo 340, Col. Villas San Sebastián, C.P. 28045, Mexico. Electronic address: carlosmh@mac.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33774512

Citation

Murillo-Zamora, E, et al. "Predictors of Severe Symptomatic Laboratory-confirmed SARS-CoV-2 Reinfection." Public Health, vol. 193, 2021, pp. 113-115.
Murillo-Zamora E, Mendoza-Cano O, Delgado-Enciso I, et al. Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection. Public Health. 2021;193:113-115.
Murillo-Zamora, E., Mendoza-Cano, O., Delgado-Enciso, I., & Hernandez-Suarez, C. M. (2021). Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection. Public Health, 193, 113-115. https://doi.org/10.1016/j.puhe.2021.01.021
Murillo-Zamora E, et al. Predictors of Severe Symptomatic Laboratory-confirmed SARS-CoV-2 Reinfection. Public Health. 2021;193:113-115. PubMed PMID: 33774512.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection. AU - Murillo-Zamora,E, AU - Mendoza-Cano,O, AU - Delgado-Enciso,I, AU - Hernandez-Suarez,C M, Y1 - 2021/02/12/ PY - 2020/10/15/received PY - 2021/01/19/revised PY - 2021/01/30/accepted PY - 2021/3/29/pubmed PY - 2021/5/14/medline PY - 2021/3/28/entrez KW - COVID-19 KW - Cohort studies KW - Prognosis KW - Reverse transcription polymerase chain reaction KW - Severe acute respiratory syndrome coronavirus 2 SP - 113 EP - 115 JF - Public health JO - Public Health VL - 193 N2 - OBJECTIVE: The aim of the study was to evaluate factors predicting severe symptomatic laboratory-confirmed (via Reverse transcription polymerase chain reaction, RT-PCR polymerase chain reaction) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. STUDY DESIGN: This is a nationwide retrospective cohort study that was conducted in Mexico. METHODS: Data from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RRs) and 95% confidence intervals (CIs) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-CoV-2 infection. RESULTS: The risk of severe disease was 14.7%, and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, P < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-CoV-2 reinfection were increasing age (RRper year = 1.007, 95% CI = 1.003-1.010), comorbidities (namely, obesity [RR = 1.12, 95% CI = 1.01-1.24], asthma [RR = 1.26, 95% CI = 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI = 1.07-1.38]), and previous severe laboratory-confirmed coronavirus disease 2019 (RR = 1.20, 95% CI = 1.03-1.39). CONCLUSIONS: To the best of our knowledge, this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-CoV-2 reinfection, and factors associated with illness severity were characterized. Our results may contribute to the current knowledge of SARS-CoV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection. SN - 1476-5616 UR - https://www.unboundmedicine.com/medline/citation/33774512/Predictors_of_severe_symptomatic_laboratory_confirmed_SARS_CoV_2_reinfection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0033-3506(21)00043-3 DB - PRIME DP - Unbound Medicine ER -